ObsEva SA Awarded Clinical Science Award for Oral Presentation at ESHRE Virtual 36th Annual Meeting, July 2020
July 15, 2020 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – July 15, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
ObsEva Announces Positive Results from two Phase 3 Studies, PRIMROSE 1 and 2, of Yselty® (linzagolix) for the Treatment of Uterine Fibroids
July 06, 2020 01:00 ET
|
ObsEva SA
PRIMROSE 1 achieved statistically significant and clinically meaningful results across primary and key secondary endpoints at week 24 PRIMROSE 2 results demonstrate sustained efficacy and...
ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020
July 03, 2020 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s...
ObsEva and Yuyuan BioScience Technology Announce Submission of the Pre-IND Dossier for Nolasiban with the Chinese NMPA
July 01, 2020 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – July 1, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN - a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA to Hold Conference Call Monday, July 6 to Discuss Results from Phase 3 PRIMROSE 1 and PRIMROSE 2 Trials Evaluating Linzagolix in Women with Uterine Fibroids
June 29, 2020 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – June 29, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve...
ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2020 Annual General Meeting held on June 9, 2020
June 09, 2020 16:01 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – June 9, 2020 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva Announces Publication of Data Showing Efficacy of Linzagolix in a Potential New Indication for Treatment of Adenomyosis
June 04, 2020 01:00 ET
|
ObsEva SA
GENEVA, Switzerland and BOSTON, MA (June 4, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive...
ObsEva SA to present at the Jefferies Virtual Healthcare Conference June 3rd, 2020
May 29, 2020 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – May 29, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive...
ObsEva Annual General Meeting 2020
May 08, 2020 16:30 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – May 8, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva Announces Publication of Abstracts from Phase 2b EDELWEISS Trial of Linzagolix in Endometriosis
April 22, 2020 16:30 ET
|
ObsEva SA
Significant improvement in quality of life outcomes maintained or increased after 52 weeks of treatment with linzagolixSmall, expected, non-clinically relevant increases in serum lipids...